GET DAILY SIGNALSArriVent BioPharma (AVBP) Analyst Target Points to +84% Upside After Clinical Setback
Key Takeaways
- The $26 central stock price target is the arithmetic mean of 11 verified analyst price targets, spanning a wide range from $15 to $45.
- AVBP recently traded near $14.16, so the target implies roughly 84% upside from current levels — a very large required move.
- Analysts remain uniformly Buy-rated, but nearly all cut their targets after the Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint in October 2026.
- Supporting factors include roughly $373 million in cash, secondary-endpoint signals, and a broader oncology pipeline; the biggest risk is that the lead program's setback weakens the core investment thesis.
- Technically, the stock sits well below its 50-day and 200-day moving averages, with support near the 52-week low and significant resistance overhead.
- For more context on this name, explore the Major News and Today's Price Move pages, as well as the Forecast and Earnings pages.
Analyst Price Targets and Consensus View
ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on oncology. Its analyst coverage shifted dramatically in October 2026, when the Phase 3 FURVENT trial of lead drug candidate firmonertinib failed to meet its primary endpoint of progression-free survival in first-line EGFR exon 20 insertion-mutated non-small cell lung cancer. I reviewed the latest targets and noticed how quickly sentiment adjusted after the readout.
Across 11 recent, attributable targets, the range runs from $15 (LifeSci Capital) to $45 (Leerink Partners), with a mean of roughly $25.55, which rounds to the $26 central target used here. Because the $45 Leerink target predates the October data readout, the remaining 10 post-revision targets average closer to $24. Targets in the most recent cycle include $27 from H.C. Wainwright, $21 from Truist, $29 from BTIG, $25 from Oppenheimer, $30 from Guggenheim, $20 from Citi, $29 from B. Riley Securities, $22 from JonesTrading, and $18 from Jefferies.
The ratings remain Buy or Strong Buy across the board, but the price targets reflect reduced conviction in the lead program. Jefferies, for example, lowered its estimate of the probability of success for exon 20 in the U.S. and EU to 25% and 15%, respectively, from 75% and 55%. The wide $15-to-$45 spread shows genuine disagreement about how much value the remaining pipeline and balance sheet justify. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With AVBP near $14.16 and a 52-week range of $11.36 to $35.83, reaching $26 would require a gain of about 84% — a very large move by any standard. Before the October setback the shares traded around $28, so $26 would essentially mean recovering most of the ground lost in the selloff.
The path would depend on restoring confidence in the pipeline. ArriVent reported some secondary-endpoint benefits and no new safety signals in FURVENT, and the molecule firmonertinib is already approved and commercialized in China by its partner Allist. If the company can reposition firmonertinib in other EGFR settings or advance its antibody-drug conjugate (ADC) programs, such as ARR-217, the valuation debate could shift. In the near term, however, the stock trades below both its 50-day and 200-day moving averages, reflecting a damaged technical profile.
What Could Support a Move Toward the Target
- Balance-sheet strength: roughly $373 million in cash and essentially no debt provide a runway to fund further development.
- Secondary signals: FURVENT showed some improvement in overall survival and no new safety concerns, which some analysts argue preserves optionality for firmonertinib.
- Validated molecule: firmonertinib's commercial success in China lends credibility to the underlying science even after the U.S. trial miss.
- Pipeline breadth: earlier-stage ADC and solid-tumor assets offer additional, if unproven, shots on goal.
- Uniform Buy ratings: every tracked analyst retains a Buy or Strong Buy rating, suggesting the post-crash price is viewed as discounted relative to residual value.
What Could Prevent the Target From Being Reached
- Lead-program uncertainty: the failed Phase 3 endpoint undermines the central investment thesis and the first-line U.S./EU opportunity.
- No revenue: as a clinical-stage company with negative EPS (earnings per share), there is no earnings-based valuation floor.
- Litigation risk: multiple securities-law investigations were announced following the October disclosure.
- Financing overhang: a $250 million at-the-market offering announced in May 2026 could dilute existing holders.
- Bearish positioning: short interest near 13.8% of shares outstanding and insider sales with no recent purchases add pressure.
Technical Levels and Market Structure
The stock is in a clear downtrend, trading near $14 versus a 52-week high of $35.83. The October capitulation low near $12 acts as near-term support, while the pre-crash consolidation and psychological levels around $15 to $18 represent initial resistance. The 50-day moving average near $22.73 and the 200-day moving average near $26.67 sit far above the current price, meaning a sustained move toward the target would require reclaiming multiple overhead levels. From what I see, the technical setup remains challenging until key moving averages are reclaimed.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state this explicitly and the October revisions show how quickly targets can shift. Investors should watch the next quarterly earnings release and guidance, any updated firmonertinib development strategy, progress on the ADC pipeline, analyst target revisions, financing activity, and the outcome of the securities investigations. No specific timing can be assigned to reaching any target.
Final Assessment
The $26 central target is the mean of 11 verified analyst targets, and it sits far above the current price near $14.16, implying roughly 84% upside. Support comes from a strong cash position, secondary clinical signals, and a diversified pipeline, while the failed Phase 3 FURVENT endpoint, litigation, dilution risk, and bearish technical structure are the principal obstacles. The $15-to-$45 target range reflects substantial disagreement about the company's residual value, so the target should be read as a statistical midpoint rather than a forecast. Whether AVBP approaches $26 will depend on evidence that the pipeline can generate value beyond the lead program's setback.
Exploring AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening alone. For investors tracking volatile names like AVBP, automated signal tools can help put daily price action and changing momentum into context. I find these signals particularly useful when evaluating names that have experienced sharp moves after clinical updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AVBP sees MACD Histogram just turned negative
AVBP saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 21 instances where the indicator turned negative. In 19 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AVBP as a result. In 31 of 36 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The 50-day moving average for AVBP moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
AVBP broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AVBP's RSI Indicator exited the oversold zone, 11 of 12 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVBP advanced for three days, in 125 of 157 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.833) is normal, around the industry mean (3.498). P/E Ratio (-3.842) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. AVBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement